Back

Angiogenic gene therapy for refractory angina: results of the epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (EXACT) phase 2 trial

25 August 2023 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Risk stratification and treatment options in chronic coronary syndrome Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Professor Thomas Povsic

Duke Clinical Research Institute, Durham (United States of America)

7 More presentations in this session

Presentation thumbnail
Treatment of microvascular angina with the coronary sinus reducer: a first experience
Doctor E. Gnan (Milan, IT)
Abstract Slides Video
Presentation thumbnail
Diagnostic performance of machine learning on 12-lead electrocardiogram for predicting multi-vessel coronary vasospastic angina
Doctor Y. Misu (Yokohama, JP)
Abstract Slides Video
Presentation thumbnail
Exercise ECG and myocardial perfusion SPECT show high prognostic value up to four years after examination
Mr M. Kraen (Malmo, SE)
Abstract Slides Video
Presentation thumbnail
The efficacy of coronary sinus reduction in refractory angina: A meta-analysis
Doctor P. Theofilis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Changes in myocardial perfusion after coronary sinus reducer implantation for refractory angina - assessment using fully automated quantitative stress perfusion cardiac MRI
Doctor K. Cheng (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Risk stratification and treatment options in chronic coronary syndrome

The Event

Event poster

ESC Congress 2023

25 August 2023 12:15 CET
You may be interested in
thumbnail
Congress Presentation
A randomized, double-blind, placebo-controlled, mechanistic trial on the safety, tolerability and pharmacodynamics of ninerafaxstat in patients with angina and chronic coronary syndrome
thumbnail
Congress Session
New trials miscellany
thumbnail
Congress Presentation
VICTOR: Vericiguat Global Study in Participants with Chronic Heart Failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources